Quantitative open-access HPLC analysis: a new calibration approach

Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-10-01-2010
Volume 22
Issue 10

A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high?performance liquid chromatography without having to prepare standards.

A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high‑performance liquid chromatography without having to prepare standards. The authors discuss the approach taken to develop the tool, its associated protocols and how it can be used to calculate data.

Read the full article here

Articles in this issue
Validating Single-Use Systems
Validating Single-Use Systems
EGA Position On The EC's Proposal For A Falisifed Medicines Directive
i1-687924-1408624996803.jpg
Green is the word
Using Certified Reference Material to Produce Compliant Water Purity Data
Using Certified Reference Material to Produce Compliant Water Purity Data
i2-687920-1408625003549.gif
News
The Pros And Cons Of Single-Use Systems
i2-687918-1408625010027.gif
Europe: A Future Leader in Vaccines?
Developing A Quality Agreement Template For Single-Use Systems
Developing A Quality Agreement Template For Single-Use Systems
Online Monitoring Of Continuous Hot Melt Extrusion
Online Monitoring Of Continuous Hot Melt Extrusion
An All-Round Excipient For Direct Compression
An All-Round Excipient For Direct Compression
Quantitative open-access HPLC analysis: a new calibration approach
i1-182996-1408680981782.jpg
Braille packaging & European generics growth
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Prepared for Health Technology Assessment Regulation Implementation

Susan Haigney
January 10th 2025
Article

The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Feliza Mirasol
January 9th 2025
Article

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products

Susan Haigney
January 3rd 2025
Article

The draft guidance document provides recommendations for complying with 21 CFR 211.110.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Announces Reopening of Comment Period Regarding HCP Immunogenicity Risk from Follow-on Recombinant Peptides

Feliza Mirasol
January 3rd 2025
Article

The comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, has been reopened by FDA until March 3, 2025.